Thanks for the quick response. You make excellent points.
When a biotech holding gets cut in two, as CTII and CEPH have, I never sell (assuming I did my homework up front) because I know how many uncertainties there are, and I know how people like to n"punish" stocks that disapoint them. I do expect a CEPH rally at some point, and I particularly admire the work CTII is doing. There may be no better way to test the efficacy of a peptide ligand than with the CTII membrane approach. By the way, I believe thats why GNE values its collaboration with CTII.
On the other hand, I think BIG drug sales and earnings will come from small molecules -- since their are now so many ways to generate and test them efficiently. Thus the real question for the investor is, would you increase your holdings of CEPH or CTII... on that question, I'm definitely on the sidelines, for now. |
